Loading...
NPI 1366474538 · Springdale, AR · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Serrhel Adams is a retina specialist (ophthalmology) physician provider located in Springdale, Arkansas. This profile covers 17 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Serrhel Adams |
| Address | 5501 Willow Creek Dr Ste 203b |
| City | Springdale |
| State | AR |
| ZIP | 72762 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | July 7, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.4M |
| Medicaid | $35.5K |
Practice scale is heavily Medicare-weighted: lifetime Medicare revenue is $3.4M compared with $35.5K in Medicaid, making Medicare the dominant payer for this provider’s billed services and indicating an effectively Medicare-centric patient population and revenue stream. The provider has been enumerated since 2006-07-07 (~20 years), consistent with an established retina practice serving a Medicare-heavy case mix.
Medicare revenue is highly concentrated in intravitreal drug administration: the precomputed top three Medicare codes (J2777, J2778, J0178) account for 74.0% of total Medicare revenue, with J2777 alone generating $1.6M (45.3% of Medicare revenue), J2778 $645.3K (18.8%), and J0178 $338.1K (9.9%). This concentration indicates the practice’s primary revenue drivers are anti-VEGF and related intravitreal biologic therapies rather than surgical retinal procedures.
Clinical/service-line patterns reinforce an injection-and-imaging retina model: high-volume codes include J2777, J2778, J0178 and procedure code 67028 (1.9K claims, $166.3K revenue), while diagnostic imaging 92134 appears frequently (3K claims, $81.2K revenue). Together these codes show a workflow focused on recurrent intravitreal injections paired with retinal imaging and office follow-up typical of medical retina care for macular diseases.
The provider is a national high-volume user for faricimab and ranibizumab: J2777 ranks #92 of 2039 providers (96th percentile) and J2778 ranks #82 of 1208 providers (93th percentile), indicating materially above-typical national volumes for these drugs and positioning the provider as a major national participant specifically for these therapies. In contrast, J0178 ranks near the middle nationally (#1928 of 3204, 40th percentile), signaling more typical adoption for aflibercept.
Operational throughput is also notable in imaging and E/M activity: 92134 is an 'extreme outlier' nationally (3K claims, $81.2K revenue; 99th percentile) and 99213 likewise is an 'extreme outlier' (1.1K claims, $64K revenue; 99th percentile). These outlier volumes imply a high-frequency clinic workflow with large numbers of imaging encounters and established-patient visits supporting ongoing injection regimens.
Medicaid activity is small and narrowly concentrated: total Medicaid revenue is $35.5K and the top Medicaid codes (led by 67028 at $28.2K, 79.4% and 92134 at $7.3K, 20.6%) account for 100.0% of Medicaid revenue, showing that Medicaid billings are essentially limited to intravitreal injections and retinal imaging. State-level ranks for these Medicaid codes are modest (#12 of 17 for 67028, 31st percentile; #28 of 43 for 92134, 36th percentile), indicating the provider is not a dominant Medicaid participant in-state.
Revenue mix exposes the practice to drug reimbursement dynamics and product mix shifts: reliance on high-cost injectable codes (J2777 $1.6M, J2778 $645.3K, J0178 $338.1K) and an entry for unclassified drugs J3490 ($233.1K, 6.8% of Medicare revenue) suggests financial sensitivity to drug pricing, reimbursement policy, and biosimilar uptake. Continued large share from a small set of biologic codes means changes in utilization patterns or reimbursement could materially affect overall revenue.
Overall competitive characterization: the provider is long-tenured (enumerated ~20 years) and functions as a high-volume, Medicare-focused retina specialist with nationally notable volume for faricimab and ranibizumab but otherwise typical volumes for many retinal procedures. For Medicaid the provider is a modest-state-level participant concentrated in injection and imaging services, while nationally the practice stands out primarily based on its faricimab and imaging throughput.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 53,640 | $30 | $1.6M |
| J2778 | Injection, ranibizumab, 0.1 mg | 3,590 | $180 | $645.3K |
| J0178 | Injection, aflibercept, 1 mg | 500 | $680 | $338.1K |
| J3490 | Unclassified drugs | 130 | $1,750 | $233.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,910 | $90 | $166.3K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,260 | $120 | $151.2K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 620 | $170 | $105.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,010 | $30 | $81.2K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,140 | $60 | $64K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 380 | $80 | $31.8K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 15 | 30 | 390 | $690 | $538.3K |
| J2777 | 1 | 20 | 12,180 | $30 | $504.5K |
| Q5124 | 1 | 10 | 620 | $170 | $105K |
| J2778 | 1 | 20 | 270 | $180 | $85K |
| J2781 | 1 | 10 | 330 | $120 | $75.8K |
| 67028 | 2 | 40 | 270 | $80 | $51.1K |
| 99214 | 1,014 | 4,300 | 130 | $70 | $18.8K |
| J3490 | 25 | 60 | 110 | $70 | $11.3K |
| 67108 | 2 | 10 | 10 | $790 | $10.3K |
| 99213 | 59 | 4,180 | 100 | $50 | $9.6K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 100 | $280 | $28.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 140 | $50 | $7.3K |
How this provider's Medicaid billing volume and revenue compare to other Arkansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arkansas median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 12 | 20 | 260 | $110 | $91.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 28 | 40 | 260 | $20 | $26.2K |
Other providers in the same ZIP code as Serrhel Adams, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.